Sapient is collaborating with Rancho Biosciences to work on accelerating the next generation of the Sapient Human Biology Database. The in-house database is already comprised of metabolomic, lipidomic, proteomic, and genomic measures collected in more than 100,000 human biosamples, alongside more than 130 million paired phenotypic data points, which Sapient utilizes in its clients’ projects to validate and mine for biomarkers, identify drug targets, and derive biological insights to inform drug development decisions.
Rancho will support an infrastructure expansion to both accelerate the ingestion of additional multi-omics and real-world data and to homogenize new and existing datasets, further increasing the breadth and depth of multidimensional insights that can be delivered, according to Tao Long, co-founder and head of data science at Sapient.
Integrated multi-omics data
“We believe strongly that integrated multi-omics data will play a critical role in the future of drug development, revealing how varied molecular interactions influence disease to enable better subtyping and drug targeting,” said Long.
“We’re investing in this future by working with Rancho on the next generation of our database. We’re creating a pathway to efficiently add more types of omics data, including more proteomics and genomics measures, alongside patient data that is standardized and curated for discovery. Ultimately this will increase the speed, versatility, and depth of our analyses along with the power of the data insights we can deliver to clients.”
Rancho reported that it will deploy subject matter experts (SMEs) versed in the curation of diverse internal and public life science datasets, including clinical trials, patient health records, and genomics, to support the project.
“Rancho’s subject matter expertise and strategic use of AI will accelerate growth of the Human Biology Database, increasing the velocity and impact of Sapient’s data analyses,” added Julie Bryant, founder, and CEO of Rancho Biosciences.
“We selected Rancho as our partner of choice not only because we found them to be best-in-class in terms of their data engineering capabilities, but also for their deep expertise in clinical data ontology,” explained Jamie Cho, head of software engineering at Sapient.
“Their understanding of real-world data architectures, combined with our expertise handling different types of omics data, is a perfect pairing to enable the next evolution of our database and support the future of insight delivery for our customers.”
